Option chain shows key data for Orgenesis's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Orgenesis.

Orgenesis (OTC:ORGS) Stock, Option Chain

Orgenesis

Orgenesis Inc is a biotech company working to unlock the potential of cell and gene therapies. It is focused on autologous therapies, with processes and systems that are developed for each therapy using a closed and automated processing system approach that is validated for compliant production near the patient for treatment of the patient at the point of care (POCare). The Company's business includes two reporting segments: Octomera and Therapies.

Wall Street

Equities

News

Eurozone

Commodities

Intraday Update

Markets

Trading Ideas

DRUG

NFLX

NKGN

NUZE

ORGS

SOBR

VTAK

Dow Falls Over 100 Points; Netflix Posts Upbeat Results

Pre-Market Outlook

Movers

AKAN

CETX

ISRG

JDZG

JTAI

MGPI

MTEM

NTBL

OLMA

PEGY

STAF

TNON

VSME

YCBD

Why Intuitive Surgical Shares Are Trading Higher By Around 7%; Here Are 20 Stocks Moving Premarket

movers image

BIVI

FLYX

FRES

FRZA

FUTU

GBNY

HSCS

JFBR

MLGO

Merrill Lynch & Strategic Return Notes for Select 10 Index

NUKK

SFIX

SNOW

UXIN

XPON

Why Maison Solutions Shares Are Trading Higher By Around 91%; Here Are 20 Stocks Moving Premarket

Orgenesis Inc

Press Releases

Germfree and Orgenesis Announce Asset Purchase and Strategic Partnership Intended to Revolutionize Cell and Gene Therapy Through Decentralized Production and Global Accessibility

Earnings

Orgenesis Provides Year End Business Update

Orgenesis Provides Business Update for the First Quarter of 2024

Orgenesis Provides Second Quarter 2024 Business Update

General

Orgenesis Announces Strategic Partnership with Harley Street Healthcare Group to Launch a State-of-the-Art Longevity & Wellness Initiative Globally

Health Care

Orgenesis Announces Positive Results From a Real-World Study of ORG-101 CAR-T Therapy in Patients with CD19+ Acute Lymphoblastic Leukemia

Orgenesis Announces Reverse Stock Split

Orgenesis Commences Trading on OTCQX® Best Market

Orgenesis Provides Third Quarter 2024 Business Update

Offerings

Orgenesis Secures Up to $5 Million Equity Investment from Williamsburg Venture Holdings

Benchmark

Comments

Orgenesis

Orgenesis (ORGS) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga